The Update of Fetal Growth Restriction Associated with Biomarkers
Abstract. Fetal growth restriction (FGR) has a prevalence of about 10% worldwide and is associated with an increased risk of perinatal mortality and morbidity. FGR is commonly caused by placental insufficiency and can begin early (<32 weeks) or in late (≥32 weeks) gestational age. A false posit...
Saved in:
Main Authors: | Liqun Sun (Author), Dandan Shi (Author) |
---|---|
Format: | Book |
Published: |
Wolters Kluwer Health,
2022-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Genetics Etiologies Associated with Fetal Growth Restriction
by: Dayuan Shi, et al.
Published: (2022) -
A Summary of Chinese Expert Consensus on Fetal Growth Restriction (An Update on the 2019 Version)
by: Fetal Medicine Subgroup, Chinese Society of Perinatal Medicine, Chinese Medical Association; Maternal-Fetal Medicine Committee, Chinese Society of Obstetrics and Gynecology, Chinese Medical Association, et al.
Published: (2022) -
Evidence-Based Screening, Diagnosis and Management of Fetal Growth Restriction: Challenges and Confusions
by: Luming Sun, et al.
Published: (2022) -
Fetal Growth Restriction: Mechanisms, Epidemiology, and Management
by: Hester D. Kamphof, et al.
Published: (2022) -
Biomarker screening in fetal growth restriction based on multiple RNA-seq studies
by: Xiaohui Li, et al.
Published: (2023)